CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway reactivation and cooperates with doxorubicin

Clinical Cancer Research

Volumn 21, Issue 1, 2015, Pages 146-156

  Guerzoni, Clara ^a   Fiori, Valentina ^b   Terracciano, Mario ^a   Manara, Maria Cristina ^a   Moricoli, Diego ^b   Pasello, Michela ^a   Sciandra, Marika ^a   Nicoletti, Giordano ^a   Gellini, Mara ^c   Dominici, Sabrina ^d   Chiodoni, Claudia ^e   Fornasari, Pier Maria ^a   Lollini, Pier Luigi ^f   Colombo, Mario P ^e   Picci, Piero ^a   Cianfriglia, Maurizio ^c   Magnani, Mauro ^b,d   Scotlandi, Katia ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b PROMETEO Laboratory STB Istituto Ortopedico Rizzoli ^*  (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d UNIVERSITY OF URBINO   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f Department of Experimental Diagnostic and Specialty Medicine Laboratory of Immunology and Biology of Metastasis   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY DABD C7; CD99 ANTIGEN; DOXORUBICIN; HEAT SHOCK PROTEIN 70; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 0662; NUTLIN 3; PROTEIN BAX; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG; ANTIIDIOTYPIC ANTIBODY; ANTINEOPLASTIC AGENT; CD99 PROTEIN, HUMAN; CELL ADHESION MOLECULE; LEUKOCYTE ANTIGEN; MDM2 PROTEIN, HUMAN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TP53 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; EWING SARCOMA; EWING SARCOMA CELL LINE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL PERMEABILITY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN TARGETING; TUMOR SUPPRESSOR GENE; UBIQUITINATION; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOSYNTHESIS; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; PATHOLOGY; SARCOMA, EWING; TUMOR CELL LINE;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTO-ONCOGENE PROTEINS C-MDM2; SARCOMA, EWING; SINGLE-CHAIN ANTIBODIES; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920698207     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0492     Document Type: Article

References (50)

1. Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 2012;30:4148-54.
2. Longhi A, Ferrari S, Tamburini A, Luksch R, Fagioli F, Bacci G, et al. Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983-2006). Cancer 2012;118:5050-9.
3. Luksch R, Tienghi A, Hall KS, Fagioli F, Picci P, Barbieri E, et al. Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation. Ann Oncol 2012;23:2970-6.
4. Scotlandi K, Baldini N, Cerisano V, Manara MC, Benini S, Serra M, et al. CD99 engagement: an effective therapeutic strategy for Ewing tumors. Cancer Res 2000;60:5134-42.
5. Scotlandi K, Perdichizzi S, Bernard G, Nicoletti G, Nanni P, Lollini PL, et al. Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewing's sarcoma. Eur J Cancer 2006;42:91-6.
6. Goodfellow P, Banting G, Sheer D, Ropers HH, Caine A, Ferguson-Smith MA, et al. Genetic evidence that a Y-linked gene in man is homologous to a gene on the X chromosome. Nature 1983;302:346-9.
7. Choi EY, Park WS, Jung KC, Kim SH, Kim YY, Lee WJ, et al. Engagement of CD99 induces up-regulation of TCR and MHC class I and II molecules on the surface of human thymocytes. J Immunol 1998; 161:749-54.
8. Kim MK, Choi YL, Kim SH, Choi EY, Park WS, Bae YM, et al. MHC class II engagement inhibits CD99-induced apoptosis and up-regulation of T cell receptor and MHC molecules in human thymocytes and T cell line. FEBS Lett 2003;546:379-84.
9. Bremond A, Meynet O, Mahiddine K, Coito S, Tichet M, Scotlandi K, et al. Regulation of HLA class I surface expression requires CD99 and p230/golgin-245 interaction. Blood 2009;113:347-57.
10. Yoon SS, Jung KI, Choi YL, Choi EY, Lee IS, Park SH, et al. Engagement of CD99 triggers the exocytic transport of ganglioside GM1 and the reorganization of actin cytoskeleton. FEBS Lett 2003;540:217-22.
11. Alberti I, Bernard G, Rouquette-Jazdanian AK, Pelassy C, Pourtein M, Aussel C, et al. CD99 isoforms expression dictates T cell functional outcomes. FASEB J 2002;16:1946-8.
12. Bixel MG, Petri B, Khandoga AG, Khandoga A, Wolburg-Buchholz K, Wolburg H, et al. A CD99-related antigen on endothelial cells mediates neutrophil but not lymphocyte extravasation in vivo. Blood 2007;109:5327-36.
13. Dworzak MN, Froschl G, Printz D, Zen LD, Gaipa G, Ratei R, et al. CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease. Leukemia 2004;18:703-8.
14. Pliyev BK, Shepelev AV, Ivanova AV. Role of the adhesion molecule CD99 605Q10 in platelet-neutrophil interactions. Eur J Haematol 2013; 91:456-61.
15. Llombart-Bosch A, Machado I, Navarro S, Bertoni F, Bacchini P, Alberghini M, et al. Histological heterogeneity of Ewing's sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support. Virchows Arch 2009;455:397-411.
16. Fisher C. Synovial sarcoma. Ann Diagn Pathol 1998;2:401-21.
17. Rajaram V, Brat DJ, Perry A. Anaplastic meningioma versus meningeal hemangiopericytoma: immunohistochemical and genetic markers. Hum Pathol 2004;35:1413-8.
18. Seol HJ, Chang JH, Yamamoto J, Romagnuolo R, Suh Y, Weeks A, et al. Overexpression of CD99 increases the migration and invasiveness of human malignant glioma cells. Genes Cancer 2012;3:535-49.
19. Lessnick SL, Ladanyi M. Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets. Annu Rev Pathol 2012;7:145-59.
20. Rocchi A, Manara MC, Sciandra M, Zambelli D, Nardi F, Nicoletti G, et al. CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. J Clin Invest 2010;120:668-80.
21. Miyagawa Y, Okita H, Nakaijima H, Horiuchi Y, Sato B, Taguchi T, et al. Inducible expression of chimeric EWS/ETS proteins confers Ewing's family tumor-like phenotypes to human mesenchymal progenitor cells. Mol Cell Biol 2008;28:2125-37.
22. Hu-Lieskovan S, Zhang J, Wu L, Shimada H, Schofield DE, Triche TJ. EWSFLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. Cancer Res 2005;65:4633-44.
23. Franzetti GA, Laud-Duval K, Bellanger D, Stern MH, Sastre-Garau X, Delattre O. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor. Oncogene 2013;32:3915-21.
24. Jung KC, Kim NH, Park WS, Park SH, Bae Y. The CD99 signal enhances Fasmediated apoptosis in the human leukemic cell line, Jurkat. FEBS Lett 2003;554:478-84.
25. Cerisano V, Aalto Y, Perdichizzi S, Bernard G, Manara MC, Benini S, et al. Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators. Oncogene 2004;23:5664-74.
26. Gellini M, Ascione A, Flego M, Mallano A, Dupuis ML, Zamboni S, et al. Generation of human single-chain antibody to the 99 cell surface determinant specifically recognizing Ewing's sarcoma sumor cells. Curr Pharm Biotechnol 2012;14:449-63.
27. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005;23:1126-36.
28. Sciandra M, Marino MT, Manara MC, Guerzoni C, Grano M, Oranger A, et al. CD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1/2. J Bone Miner Res 2014;29:1295-309.
29. Chou TC. Assessment of synergistic and antagonistic effects of chemotherapeutic agents in vitro. Contrib Gynecol Obstet 1994;19:91-107.
30. Bennett MR. Mechanisms of p53-induced apoptosis. Biochem Pharmacol 1999;58:1089-95.
31. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, et al. Molecular characterization of commonly used cell lines for bone tumor research: a trans-European Euro BoNet effort. Genes Chromosomes Cancer 2010;49:40-51.
32. Zhang W, Funk WD, Wright WE, Shay JW, Deisseroth AB. Novel DNA binding of p53 mutants and their role in transcriptional activation. Oncogene 1993;8:2555-9.
33. Chan KT, Lung ML. Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line. Cancer Chemother Pharmacol 2004;53:519-26.
34. Neilsen PM, Pishas KI, Callen DF, Thomas DM. Targeting the p53 Pathway in Ewing Sarcoma. Sarcoma 2011;2011:746939.
35. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299-303.
36. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-8.
37. Gordon MD, Corless C, Renshaw AA, Beckstead J. CD99, keratin, and vimentin staining of sex cord-stromal tumors, normal ovary, and testis. Mod Pathol 1998;11:769-73.
38. Husak Z, Dworzak MN. CD99 ligation upregulates HSP70 on acute lymphoblastic leukemia cells and concomitantly increases NK cytotoxicity. Cell Death Dis 2012;3:e425.
39. Bernard G, Breittmayer JP, de Matteis M, Trampont P, Hofman P, Senik A, et al. Apoptosis of immature thymocytes mediated by E2/CD99. J Immunol 1997;158:2543-50.
40. Imbert AM, Belaaloui G, Bardin F, Tonnelle C, Lopez M, Chabannon C. CD99 expressed on human mobilized peripheral blood CD34+ cells is involved in transendothelial migration. Blood 2006;108:2578-86.
41. Amaral AT, Manara MC, Berghuis D, Ordonez JL, Biscuola M, Lopez-García MA, et al. Characterization of human mesenchymal stemcells from Ewing sarcoma patients: pathogenetic implications. PLoS ONE 2014;9 e85814.
42. Wittel UA, Jain M, Goel A, Chauhan SC, Colcher D, Batra SK. The in vivo characteristics of genetically engineered divalent and tetravalent singlechain antibody constructs. Nucl Med Biol 2005;32:157-64.
43. Rudnick SI, Adams GP. Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm 2009;24:155-61.
44. Husak Z, Printz D, Schumich A, Potschger U, Dworzak MN. Death induction by CD99 ligation in TEL/AML1-positive acute lymphoblastic leukemia and normal B cell precursors. J Leukoc Biol 2010;88:405-12.
45. Accardi L, Di Bonito P. Antibodies in single-chain format against tumour-associated antigens: present and future applications. Curr Med Chem 2010;17:1730-55.
46. Ladanyi M, Lewis R, Jhanwar SC, Gerald W, Huvos AG, Healey JH. MDM2 and CDK4 gene amplification in Ewing's sarcoma. J Pathol 1995;175:211-7.
47. Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol 2013;65:157-70.
48. Dworzak MN, Fritsch G, Buchinger P, Fleischer C, Printz D, Zellner A, et al. Flow cytometric assessment of human MIC2 expression in bone marrow, thymus, and peripheral blood. Blood 1994;83:415-25.
49. Stork R, Campigna E, Robert B, Muller D, Kontermann RE. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J Biol Chem 2009;284:25612-9.
50. Dotto GP. p21(WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta 2000;1471:M43-56.